Cizzle Biotechnology Holdings PLC Result of AGM
24 Giugno 2024 - 1:42PM
RNS Regulatory News
RNS Number : 6238T
Cizzle Biotechnology Holdings PLC
24 June 2024
24
June 2024
Cizzle Biotechnology Holdings
Plc
("Cizzle
Biotechnology" or the "Company")
Result of
AGM
Cizzle Biotechnology, the UK-based
diagnostics developer, announces that at the Annual General Meeting
("AGM") of the Company held earlier today, all resolutions were
voted on by a show of hands and were passed.
The proxy votes cast in respect of
the resolutions were as follows:
|
Resolution
|
For
|
Against
|
Votes
withheld
|
|
Total votes
|
%
|
Total votes
|
%
|
|
|
1. To receive the Company's
annual report and accounts for the year ended 31 December
2023
|
75,934,412
|
93.27
|
5,924,896
|
6.73
|
2
|
|
2. To approve the
Directors' Remuneration Report
|
75,900,186
|
93.23
|
5,924,896
|
6.77
|
10
|
|
3. To re-appoint John
Michael Treacy as a Director of the Company
|
74,370,196
|
91.35
|
5,924,896
|
8.65
|
2
|
|
4. To re-appoint Dawn
Coverly as a Director of the Company
|
75,700,196
|
92.98
|
5,924,896
|
7.02
|
0
|
|
5. To re-appoint Nigel
Ronald Lee as a Director of the Company
|
75,734,386
|
93.03
|
5,924,896
|
6.97
|
2
|
|
6. To re-appoint PKF
Littlejohn LLP as auditor of the Company
|
75,734,398
|
93.03
|
5,924,896
|
6.97
|
0
|
|
7. To authorise the
Directors to determine the auditor's remuneration
|
75,734,396
|
93.03
|
5,924,896
|
6.97
|
2
|
|
8. Authorises the Directors to allot shares in the Company
or to grant rights to subscribe for, or to convert any security
into, shares in the Company
|
72,596,681
|
89.17
|
5,924,896
|
10.83
|
0
|
|
9. Authorise the
Directors to allot equity securities disapplying pre-emption
rights
|
73,960,822
|
90.92
|
6,175,857
|
9.08
|
63,555
|
|
10. That General Meetings may be
called on not less than 14 days' notice
|
67,739,369
|
92.52
|
6,175,857
|
7.48
|
8,195,045
|
Enquiries:
|
Cizzle Biotechnology Holdings plc
|
Via IFC Advisory
|
|
Allan Syms (Executive
Chairman)
|
|
|
Allenby Capital Limited
|
+44(0) 20 3328 5656
|
|
John Depasquale/George Payne
(Corporate Finance)
|
|
|
Stefano Aquilino/Amrit Nahal (Sales
and Corporate Broking)
|
|
|
Novum Securities Limited
|
+44(0) 20 7399 9400
|
|
Colin Rowbury
Jon Bellis
|
|
|
IFC
Advisory Limited
|
+44(0) 20 3934 6630
|
|
Tim Metcalfe
|
|
|
Florence Chandler
|
|
About Cizzle Biotechnology
Cizzle is developing a blood test
for the early detection of lung cancer. The Company is a spin- out
from the University of York, founded in 2006, around the work of
Professor Coverley and colleagues. Its proof-of-concept prototype
test is based on the ability to detect a stable plasma biomarker, a
variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell
nuclear protein involved in DNA replication, and the targeted CIZ1B
variant is highly correlated with early-stage lung cancer. For more
information, please see https://cizzlebiotechnology.com
You can also follow the Company
through its twitter account @CizzlePlc and on LinkedIn.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
RAGSEFFFLELSELM
Grafico Azioni Cizzle Biotechnology (LSE:CIZ)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Cizzle Biotechnology (LSE:CIZ)
Storico
Da Dic 2023 a Dic 2024
